ESC 365 - Aspirin in primary prevention. Risks and benefits. Up date 2019. A meta-analysis

ESC Premium Access

Aspirin in primary prevention. Risks and benefits. Up date 2019. A meta-analysis

Session: Poster Session 1 - Atrial fibrillation, anti-platelet therapy, anticoagulation and bleeding

Topic: Cardiovascular Risk Assessment

Speaker: Doctor L. Lobo (Buenos Aires, AR)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Lorenzo Martin Lobo

Campo de Mayo Military Hospital, Buenos Aires (Argentina)

0 follower

12 more presentations in this session

Risk of major gastrointestinal bleed in relation to vascular disease risk in 0.5M UK Biobank participants

Speaker: Doctor I. Hammami (Oxford, GB)

Anticoagulation strategies based on warfarin or direct oral anticoagulants compared to major hemorrhagic events: the relevance of patients aged 75 years or older.

Speaker: Doctor A. Conti (Massa, IT)

CHA(2)DS(2)-VASc score calibration in anticoagulated vs non-anticoagulated patients in a healthcare area

Speaker: Doctor A. Baluja (Santiago de Compostela, ES)

The effect of hypertension and metabolic syndrome on left atrial function in patients with paroxysmal atrial fibrillation undergoing catheter ablation

Speaker: Doctor A. Katbeh (Aalst, BE)

Nocturnal hypoxemic burden in ambulatory patients with atrial fibrillation: a disease-orientated assessment of sleep-disordered breathing severity.

Speaker: Professor D. Linz (Maastricht, NL)

Access the full session

Poster Session 1 - Atrial fibrillation, anti-platelet therapy, anticoagulation and bleeding

Speakers: Doctor L. Lobo, Doctor I. Hammami, Doctor A. Conti, Doctor A. Baluja, Doctor A. Katbeh...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources